Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human)
Payments companies reported to CMS as associated with Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human). "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human), per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human)
These are the largest totals companies reported as associated with Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human). They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jill Johnsen | Seattle, WA | Hematology & Oncology | $761,971.90 |
| Robert Sidonio | Atlanta, GA | Pediatric Hematology-Oncology | $69,218.95 |
| Nathan Connell | Boston, MA | Hematology (Internal Medicine) | $36,294.50 |
| Fernando Corrales-Medina | Miami, FL | Pediatric Hematology-Oncology | $19,507.24 |
| Craig Kessler | Washington, DC | Hematology & Oncology | $18,255.31 |
| Veronica Flood | Milwaukee, WI | Pediatric Hematology-Oncology | $15,200.73 |
| Angela Weyand | Ann Arbor, MI | Pediatric Hematology-Oncology | $13,570.49 |
| Jennifer Davila | Bronx, NY | Pediatric Hematology-Oncology | $11,343.88 |
| Allison Wheeler | Seattle, WA | Pediatric Hematology-Oncology | $9,886.68 |
| Catherine Mcguinn | New York, NY | Pediatric Hematology-Oncology | $9,766.71 |
Prescribed Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human)?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.